Lantermans, Hildo C.
Ma, Fangxue
Kuil, Annemieke
van Kesteren, Sanne
Yasinoglu, Sevtap
Yang, Guang http://orcid.org/0000-0003-3049-4200
Buhrlage, Sara J. http://orcid.org/0000-0003-4562-1823
Wang, Jinhua http://orcid.org/0000-0002-1214-4103
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Kersten, Marie José http://orcid.org/0000-0002-8904-3802
Treon, Steven P. http://orcid.org/0000-0001-6393-6154
Pals, Steven T.
Spaargaren, Marcel http://orcid.org/0000-0002-3135-5109
Funding for this research was provided by:
KWF Kankerbestrijding (7873)
International Waldenstrom’s Macroglobulinemia Foundation
Lymph&Co
Lymph&Co
International Waldenstrom’s Macroglobulinemia Foundation
Lymph&Co
Lymph&Co
CSC | Chinese Government Scholarship
Article History
Received: 3 August 2023
Revised: 15 February 2024
Accepted: 26 February 2024
First Online: 7 March 2024
Competing interests
: JW is a consultant and equity holder for Soltego. NSG is a founder, a science advisory board member, and an equity holder in Syros, Lighthorse, Inception, C4, B2S, Allorion, Voronoi, Matchpoint, Shenandoah (board member), Larkspur (board member), and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voronoi, Arbella, Epiphanes, Deerfield, Springworks, Interline, and Sanofi. MK reports honoraria from Kite/Gilead, Novartis, Miltenyi Biotech, Roche, and Bristol Myers Squibb/Celgene; consultancy or advisory role for Kite/Gilead, Roche, Bristol Myers Squibb/Celgene, Novartis, Miltenyi Biotech and Adicet Bio; research funding from Kite/Gilead, Roche, Takeda, and Bristol Myers Squibb/Celgene; and travel support from Kite, Roche, Novartis, and Miltenyi Biotech. SPT has received consulting fees and research funding from Janssen, Abbvie/Pharmacyclics, Beigene, Eli Lilly, and X4 Pharmaceuticals. SPT’s institution (DFCI) holds a patent for KIN-8194 development. The other authors declare no relevant conflict of interest.